Exos Asset Management’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Exos Asset Management’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$736K	Sell	75,929 -1,022	-1%	-$9.94K	0.38%	85
2022 Q1	$748K	Buy	76,951 +3,402	+5%	+$32.9K	0.32%	98
2021 Q4	$722K	Buy	+73,549	New	+$721K	0.37%	91

Other funds holding DALS

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Exos Asset Management's DALS Position: Q2 2022 in Review

Exos Asset Management reduced its DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) stake by 1.3% in Q2 2022, selling an estimated $9.94K and leaving 75,929 shares worth $736K. The position accounts for 0.38% of the portfolio, ranked #85.

Exos Asset Management first reported a position in DALS in Q4 2021 and has held it in 3 quarters since. The position peaked at $748K in Q1 2022. 45 funds tracked by Wall St. Rank hold DALS as of Q2 2022.

Exos Asset Management held 75,929 shares of DA32 Life Science Tech Acquisition Corp. Class A Common Stock worth $736K as of Q2 2022.
Exos Asset Management sold 1,022 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q2 2022, an estimated $9.94K.
DA32 Life Science Tech Acquisition Corp. Class A Common Stock made up 0.38% of Exos Asset Management's portfolio in Q2 2022, its #85 holding.
Exos Asset Management first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q4 2021 and has held it in 3 quarters since.
Exos Asset Management's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $748K in Q1 2022.
45 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q2 2022.

Based on Exos Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.